TABLE 3.
Distribution of CNS/TF-binding sites amongrab genes and their role in Zmrab17 activity
| CNS-TF-binding sitesa
|
Zmrab17 activityb
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Os
|
Shoot
|
|||||||||
| TF/CNS | Zm: rab17 |
Sb: dhn2S |
16A2 | 16A | 16B | 16C | 16D | −ABA | +ABA | Embryo: +ABA |
| CNS (17) | + | + | + | + | + | 6/7 | + | |||
| DRE1 | + | + | + | + | − | − | − | o | ++ | |
| ABRE1 (16) | + | + | + | + | + | + | + | o | + | +++ |
| DRE2 (15) | + | + | + | + | + | + | − | +++ | ++ | +++ |
| ABRE2 (14) | + | + | + | + | + | + | − | o | + | ++ |
| CNS (13.1) | − | − | + | + | + | − | + | |||
| CNS (13) | + | + | + | + | − | − | − | |||
| ABRE3a/3b | + | + | − | − | − | − | − | o | + | + |
| CNS (12.1) | + | + | − | − | + | + | − | |||
| GRA (12) | + | − | + | + | − | − | − | +++ | ++ | o |
| CNS (11.2) | − | − | + | + | + | 6/7 | − | |||
| SPH (11.1) | + | + | − | − | 6/7 | + | + | − | + | + |
| ABRE4 (11) | + | + | + | + | + | + | − | + | ++ | +++ |
| CNS (10) | + | − | + | + | − | + | − | |||
| CNS (9) | + | + | + | + | − | − | + | |||
| CNS (8) | + | + | + | + | + | − | + | |||
| TATA (7) | + | + | + | + | + | + | 6/7 | |||
| CNS (6) | + | + | + | + | 6/7 | − | − | |||
| CNS (5) | + | − | + | + | − | − | − | |||
“+” indicates that the element contains a biochemically defined TF-binding site or a CNS meeting the 7 of 8 base-pair match criteria; 6/7 tracks sequences that were not identified as 7/8 CNS, yet contain a 6 of 7 base-pair match to the CNS; “−” indicates that the element is not present in that lineage.
“+++” indicates that the element is required for expression; “++” indicates that the element contributes moderately to expression; “+” indicates that the element contributes slightly to gene expression; “o” indicates that the element does not contribute to gene expression under the given condition; − indicates that the element represses gene expression (data from Busk et al. 1997).